Dr. Osterman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
21 Hospital Dr
Asheville, NC 28801Phone+1 828-253-4262
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2018 - 2021
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2015 - 2018
- Uconn School Of MedicineClass of 2015
Certifications & Licensure
- NC State Medical License 2018 - 2025
- PA State Medical License 2015 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 60 citationsPhase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerTracy L. Rose, Michael R. Harrison, Allison M. Deal, Sundhar Ramalingam, Young E. Whang
Journal of Clinical Oncology. 2021-08-24 - 14 citationsEfficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.Chelsea K. Osterman, Dilip Sankar Babu, Daniel M. Geynisman, Bianca Lewis, Robert A. Somer
The Oncologist. 2019-05-01 - 35 citationsEfficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.Vadim S Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman
Cancer. 2022-03-15
Press Mentions
- Symptomatic Bladder Cancer Recurrence Linked with Worse SurvivalJune 29th, 2017
- Symptomatic Bladder Cancer Recurrence Linked with Worse SurvivalJune 29th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: